• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Radiomics to Predict Response to Antiangiogenic Therapy in Glioblastoma


Radiomic combines imaging and computational technologies and can identify patients with recurrent glioblastoma who may benefit from using angiogenesis inhibitors.

A noninvasive approach devised by clinical researchers at the University of Heidelberg in Germany has combined imaging and computational technologies to identify patients with recurrent glioblastoma who may benefit from using angiogenesis inhibitors.

Currently, treatment with the antiangiogenic monoclonal antibody, bevacizumab, is the standard of care in patients with recurrent glioblastoma. However, patient response to this treatment cannot be predicted. According to the paper, published in Clinical Cancer Research, the authors used a technique called radiomics, whereby quantitative magnetic resonance imaging features from 172 patients were extracted prior to their treatment with the drug. The patients were divided into a discovery and a validation set.

“Radiomics is a noninvasive approach that applies advanced computational methods to convert medical images of cancerous tissues into a large number of quantitative descriptors encompassing a wealth of hidden information, much more than what is visible when looking at the images with the naked eye,” Philipp Kickingereder, MD, the study’s lead author, said in a statement. The images are then subjected to machine learning, and predictive models can be developed that can allow patient stratification, he added.

In the current study, the model stratified patients in the discovery cohort into low- or high-risk groups for progression-free survival (PFS) (hazard ratio [HR] = 1.60; P = .017) and overall survival (OS) (HR = 2.14; P<.001). The outcomes were validated using data on patients in the validation set (HR = 1.85, P = .030 for PFS; HR = 2.60, P = .001 for OS). PFS and OS were measured from the time of treatment with bevacizumab until disease progression and death or last follow-up.

In the discovery set, median PFS and OS for the low-risk group were 5.9 months and 11.8 months, respectively; median PFS and OS in the high-risk group were 3.8 months and 6.5 months, respectively. In the matched validation cohort, median PFS and OS for the low-risk group were 5.6 months and 11.6 months, respectively; for the high risk group, they were 2.7 months and 6.5 months, respectively.

Being noninvasive, “Sophisticated imaging analysis may in the future provide valuable complementary information to histological and molecular data,” Kickingereder said.

Related Videos
dr marisa mcginley
Mila Felder, MD, FACEP
Video 1 - "NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer"
Camilla Levister
Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic
Video 12 - "Key Considerations for Treating Patients Diagnosed With CLL and SLL"
Video 11 - "Optimizing BTKi Treatment Strategies"
Video 13 - "Other Clinical Considerations in Demodex Blepharitis Treatment"
Related Content
© 2024 MJH Life Sciences
All rights reserved.